Live Fertility Q&A Schedule

Understanding President Trump’s IVF Coverage Expansion Announcement

On October 16, 2025, President Trump announced that a recent agreement with EMD Serono and additional proposed policy measures should result in fertility drug discounts and expanded fertility treatment coverage. The proposed fertility drug cost reduction and IVF coverage expansion announcement has drawn national attention as being a step in the right direction for increasing equitable access to life-changing healthcare; however, many current and prospective patients are justifiably uncertain as to when and how these measures may make a difference in their own family building journeys.

It’s important to break down the recent Trump IVF announcement to understand the newfound potential benefits and limitations so that fertility patients are empowered to make the right decisions for their individualized treatment plans.

What the Announcement Includes

The Trump IVF announcement of 2025 introduced several proposals designed to make fertility care more affordable and accessible:

Discounted Fertility Medications

Pharmaceutical manufacturer EMD Serono and Trump’s administration have reached an agreement which will result in fertility drug cost reduction to align with the lowest prices being paid by other developed nations (most-favored nation or MFN price).

Launching in early 2026, the website TrumpRx.gov will connect patients directly with this fertility drug manufacturer, allowing eligible citizens to purchase fertility medications such as Gonal-F and Pergoveris at additionally discounted rates.

In particular:

• Low- and middle-income patients (earning below roughly $115,000 per year, or 550% of the federal poverty level) would qualify for additional discounts.
• These discounted rates are also expected to extend to State Medicaid programs once the plan is active.

New Employer Fertility Benefit Option

Employers will soon have the option to offer standalone fertility benefit packages, similar to how vision or dental coverage is provided.

Of note:

• This new fertility benefits employer insurance model would be entirely voluntary unless required by state law.
• Employers could choose to add these benefits separately from major medical coverage, offering another potential route to help employees manage the cost of treatment.

Investment and FDA Initiatives

The plan also includes commitments from EMD Serono to expand U.S. manufacturing and participate in an FDA program that prioritizes review of lower-cost fertility medications — part of a broader effort to support IVF cost reduction nationwide.

What It Means Right Now

While these proposals signal progress, it’s important to know what’s not yet guaranteed.

“It’s heartening to see national attention on the barriers that infertility patients face,” said Boston IVF’s Dr. Alan Penzias, Regional Medical Director of IVI RMA North America. “Any step that highlights the need for accessible fertility care is positive, but it’s important to remember that real progress takes time. Patients should stay informed and work closely with their care teams to make decisions based on their current options rather than waiting for policies that may evolve slowly or unevenly.”

Important facts to consider:

• Discounts are not immediate. The new IVF drugs discount program will not go live until early 2026.
• Savings will vary. While exact discounts will depend upon dosage and eligibility, it is estimated that eligible candidates can save up to $2,200 per cycle in medication savings.
• Coverage remains optional. Employers are not required to offer fertility benefits unless mandated by state law.
• No change to clinical costs. The policy focuses on medication pricing and benefit design — not on procedure or lab costs such as monitoring, retrievals, or embryo freezing.
• Implementation could take time. Smaller employers and insurers may need a full plan year to update offerings once guidance is finalized.
• Inclusive access is essential. While the announcement often refers to women’s access, infertility affects all genders and family types — a point advocates are urging policymakers to keep front and center.

What Patients Should Do Now

Fertility care is highly personal, and timing is oftentimes critical. While future cost reductions are encouraging, waiting for policies that are still in development may not always be the best choice.

“For many individuals and couples, time is the single most important factor in fertility treatment,” said Dr. Penzias. “While proposed changes to expand coverage are promising, the best approach is to act based on your personal medical timeline. Our goal is to help every patient move forward with confidence—combining medical insight, financial guidance, and compassion to create the best possible chance for success right now.”

At Boston IVF, our team encourages patients to:

• Speak with your physician to discuss your individualized treatment options and ideal timeline.
• Confer with our financial coordinators to review your insurance coverage, discuss available financial discount programs, and explore potential candidacy for benefiting from the measures introduced in the announcement.
• Talk to your employer about expanding or offering fertility coverage, especially in light of the new standalone benefit option announced by Trump.

FAQs: The Trump IVF Coverage Expansion

Can I access discounted fertility medications through TrumpRx.gov right now?

Not yet. The new TrumpRx.gov platform is expected to launch in early 2026. Until then, patients should continue obtaining prescriptions through their current specialty pharmacy or discuss existing manufacturer discount programs with our financial counseling team.

Who may qualify for the new fertility drug discounts?

Eligibility will depend on income. The current proposal indicates that patients earning below approximately 550% of the Federal Poverty Level (around $115,000 for an individual) will qualify for the most significant savings once the program becomes active.

How much could patients save on fertility medications?

While individual savings will vary, the administration estimates potential savings of up to $2,200 per IVF cycle. Actual costs will depend on dosage, medication type, and eligibility once the program begins.

Will my employer automatically offer expanded fertility coverage?

No. The new benefit structure allows—but does not require—employers to provide standalone fertility benefits, similar to dental or vision coverage. Employers may choose to add this benefit in future plan years once additional federal guidance is released.

Does this announcement cover all aspects of IVF treatment?

Not at this time. The current policy focuses on medication cost reduction and benefit design, but does not address other clinical costs such as monitoring, lab work, or embryo storage.

What can I do now to prepare for these potential changes?

Patients are encouraged to continue their care without delay. Boston IVF’s financial coordinators can help review your current insurance coverage, identify available medication discounts, and estimate potential future savings once the new programs take effect.

Next Steps

While Trump’s recent IVF coverage expansion and fertility drug discount announcement appears to be a promising step forward for fertility care being recognized as essential health care that must become more accessible. However, the true benefits and limitations of this announcement await to be seen. In the meantime, policymakers and advocates must remain vigilant in promoting awareness for equitable access to fertility care.

At Boston IVF, we remain focused on what matters most: ensuring every patient has access to accurate information, personalized financial guidance, and the highest quality care on their path to parenthood. Ready to take the next step?

Schedule a consultation with a Boston IVF specialist today.